Podcasts about Commission

"We proposed a concept to the American Society of Clinical Oncology (ASCO), recognizing that extravasation management requires significant interdisciplinary collaboration and rapid action. There can occasionally be uncertainty or lack of clear guidance when an extravasation event occurs, and our objective was to look at this evidence with the expert panel to create a resource to support oncology teams overall. We hope that the guideline can help mitigate harm and improve patient outcomes," Caroline Clark, MSN, APRN, AGCNS-BC, OCN®, EBP-C, director of guidelines and quality at ONS, told Chelsea Backler, MSN, APRN, AGCNS-BC, AOCNS®, VA-BC, oncology clinical specialist at ONS, during a conversation about the ONS/ASCO Guideline on the Management of Antineoplastic Extravasation. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 2, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the management of antineoplastic extravasation. Episode Notes  Complete this evaluation for free NCPD. ONS/ASCO Guideline on the Management of Antineoplastic Extravasation ONS Podcast™ episodes: Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 335: Ultrasound-Guided IV Placement in the Oncology Setting Episode 145: Administer Taxane Chemotherapies With Confidence Episode 127: Reduce and Manage Extravasations When Administering Cancer Treatments ONS Voice articles: Access Devices and Central Lines: New Evidence and Innovations Are Changing Practice, but Individual Patient Needs Always Come First New Extravasation Guidelines Provide Recommendations for Protecting Patients and Standardizing Care Standardizing Venous Access Assessment and Validating Safe Chemo Administration Drastically Lowers Rates of Adverse Venous Events This Organization's Program Trains Non-Oncology Nurses to Deliver Antineoplastic Agents Safely ONS books: Access Device Guidelines: Recommendations for Nursing Practice and Education (fourth edition) Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Clinical Guide to Antineoplastic Therapy: A Chemotherapy Handbook (fourth edition) ONS courses: Complications of Vascular Access Devices (VAD) and IV Therapy ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ ONS Oncology Treatment Modalities Clinical Journal of Oncology Nursing articles: Chemotherapy Extravasation: Incidence of and Factors Associated With Events in a Community Cancer Center Standardized Venous Access Assessment and Safe Chemotherapy Administration to Reduce Adverse Venous Events Oncology Nursing Forum article: Management of Extravasation of Antineoplastic Agents in Patients Undergoing Treatment for Cancer: A Systematic Review ONS huddle cards: Antineoplastic Administration Chemotherapy Immunotherapy Implanted Venous Port ONS position statements: Administration (Infusion and Injection) of Antineoplastic Therapies in the Home Education of the Nurse Who Administers and Cares for the Individual Receiving Antineoplastic Therapies ONS Guidelines™ for Extravasation Management ONS Oncologic Emergencies Learning Library ONS/ASCO Algorithm on the Management of Antineoplastic Extravasation of Vesicant or Irritant With Vesicant Properties in Adults American Society of Clinical Oncology (ASCO) Podcast: Management of Antineoplastic Extravasation: ONS-ASCO Guideline To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "The focus of this guideline was specifically on intravenous antineoplastic extravasation or when a vesicant or an irritant with vesicant properties leaks out of the vascular space. This can cause an injury to the patient that's influenced by several factors including the specific drug that was involved in the extravasation, whether it was DNA binding, how much extravasated, the affected area, and individual patient characteristics." TS 1:48 "The panel identified and ranked outcomes that mattered most with extravasation. Not surprising, one of the first was tissue necrosis. Like, 'How are we going to prevent tissue necrosis and preserve tissue?' The next were pain, quality of life, delays in cancer treatment: How is an extravasation going to delay cancer treatment that's vital to the patient? Is an extravasation also going to result in hospitalization or additional surgical interventions that would be burdensome to the patient? ... We had a systematic review team that then went in and summarized the data, and the panel applied the grading of recommendations, assessment, development, and evaluation (GRADE) criteria, grading quality of evidence and weighing factors like patient preferences, cost, and feasibility of an intervention. From there, they developed their recommendations." TS 7:35 "The panel, from the onset, wanted to make sure we had something visual for our readers to reference. They combined evidence from the systematic review, other scholarly sources, and their real-world clinical experience to make this one-page supplementary algorithm. They wanted it to be comprehensive and easy to follow, and they included not only those acute management steps but also guidance on 'How do I document this and what are the objective and subjective assessment factors to look at? What am I going to tell the patient?' In practice, for use of that, I would compare it to your current processes and identify any gaps to inform policies in your individual organizations." TS 16:34 "The guidelines don't take place of clinician expertise; they're not intended to cover every situation, but a situation that keeps coming up that we should talk about as a limitation, is we're seeing these case reports of tissue injury with antibody–drug conjugate extravasation. There's still not enough evidence to inform care around the use of antidotes with those agents, so this still needs to be addressed on a case-by-case basis. We still need publication of those case studies, what was done, and outcomes to help inform direction." TS 19:24 "Beyond the acute management is to ensure thorough documentation regarding extravasation. Whether you're on electronic documentation or on paper, are the prompts there for the nurse to capture all of the factors that should be captured regarding that extravasation? The size, the measurement, the patient's complaints. Is there redness? Things like that. And then within the teams, everyone should know where to find that initial extravasation assessment so that later on, if they're in a different clinic, they have something to go by to see how the extravasation is healing or progressing. ... I think there's an importance here, too, to our novice oncology nurses and their preceptors. This could be anxiety-provoking for the whole team and the patient, so we want to increase confidence in management. So, I think using these resources for onboarding novice oncology nurses is important." TS 22:34

2026 - Bliain Úr faoi Mhaise DaoibhseA very happy New Year to all readers of this column, to the staff of the Belfast Media Group and The Irish Echo. And to you good readers who have stayed with me over the years.None of us know what 2026 will bring but we can be sure it will be interesting. May it also be good to you all and to your families. Beirigí bua. Eyes On The Prize. 2025 was a good year for Irish Unity. All of those advocating for a new Ireland, including Sinn Féin's Commission on the Future of Ireland, worked hard and effectively promoting the message that Irish Unity will be good for the people of the island of Ireland. Crucially, both houses of the Oireachtas, the Dáil and the Seanad, passed motions calling on the Irish government to begin the process of planning and preparing for Unity referendums. These include The Oireachtas Good Friday Agreement Committee. This is the only all-Ireland committee in Leinster House. It is unique in that Members of Parliament from the north join TDs and Senators to work on issues relating to the implementation of the Good Friday Agreement.The Good Friday Agreement remains the basis for relations on the island of Ireland and between the islands of Ireland and Britain. However, its implementation has been challenged, principally by indifference from London and a lack of consistent and positive leadership from Dublin.‘I'm so scared, please come'For as long as I have been a republican activist I have been reading and writing about the impact of British colonialism on peoples around the world. As the largest empire in human history Britain's conquests and exploitation of other places resulted in untold misery, death and hardship for those living under British rule - not least here in Ireland. To maintain its domination, the British Empire used violence and dehumanised the peoples it sought to exploit. Behind its claim of being a guardian of the ‘rule of law' Britain stole land and property, exploited mineral resources and reduced native peoples to little more than slaves.Among those many locations was Palestine. British policy is largely responsible for the decades of war that have plighted that land for a hundred years. Current British government policy is facilitating the genocide of the Palestinian people by the Israeli apartheid regime.I have visited Palestine and Israel on at least four occasions, including the Gaza Strip in 2009. I walked along the ‘separation wall' – a monstrous perversion designed to imprison Palestinians into smaller and smaller ghettoes.

Zain Johnson spoke to the Water Research Commission about concerns that SA will run out of water by 2030 Views and News with Clarence Ford is the mid-morning show on CapeTalk. This 3-hour long programme shares and reflects a broad array of perspectives. It is inspirational, passionate and positive. Host Clarence Ford’s gentle curiosity and dapper demeanour leave listeners feeling motivated and empowered. Known for his love of jazz and golf, Clarrie covers a range of themes including relationships, heritage and philosophy. Popular segments include Barbs’ Wire at 9:30am (Mon-Thurs) and The Naked Scientist at 9:30 on Fridays. Thank you for listening to a podcast from Views & News with Clarence Ford Listen live on Primedia+ weekdays between 09:00 and 12:00 (SA Time) to Views and News with Clarence Ford broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/erjiQj2 or find all the catch-up podcasts here https://buff.ly/BdpaXRn Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567See omnystudio.com/listener for privacy information.

Gurbaj Singh Multani is just playing basketball when the ceremonial dagger that symbolizes his Sikh faith falls onto the playground of his Montreal school. The next thing the 11-year-old knows, his principal is giving him an ultimatum: hand over his kirpan, a symbol of his Sikh faith, or leave school. This week, This is Montreal shares this episode of the CBC podcast See You in Court. Host Falen Johnson and journalist Sonali Karnick take us through the case of Multani v Commission scolaire Marguerite-Bourgeoys. It sparks a heated public debate over multiculturalism in post 9/11 Quebec, with grown-ups hurling slurs at the tween, and ends with a landmark ruling for religious freedoms in Canada. Check out more episodes of See You in Court

On New Year's Eve, America250 Commission Chair Rosie Rios talks about the special celebrations tonight related to the U.S.'s 250th birthday in 2026, New York City & New Orleans are among the cities increasing their New Year's Eve security and world leaders issue New Year's messages; House Republicans schedule a hearing looking at Minnesota social welfare programs fraud, inviting both Republican state lawmakers and Gov. Tim Walz (D-MN) to testify; number of Jeffrey Epstein-related files the Justice Department is working through to release now reportedly tops 5 million; New York City mayor-elect Zohran Mamdani (D) names a new schools chancellor a day before he takes office; former Sen. Ben Nighthorse Campbell (D-CO) has died. We  hear his 2004 remarks at the dedication for the Smithsonian Institution's National Museum of the American Indian. Learn more about your ad choices. Visit megaphone.fm/adchoices

Mia Horowitz, PhD, Tel Aviv University; Aitor Aguirre, PhD, Michigan State University, Michigan, USA; and Ying Sun, PhD, University of Cincinnati, discuss the use of organoid models in lysosomal disorder research and drug development.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session3-organoids-and-lab-grown-models-in-lysosomal-disorders/Learning ObjectivesDescribe the use of heart organoid models to better understand the pathophysiology of lysosomal disorders and its clinical relevanceDescribe the use and application of brain organoid models in neuropathic Gaucher disease research and treatmentFacultyMia Horowitz, PhD, Shmunis School of Biomedicine and Cancer Research, George S. Wise Faculty of Life Sciences, Tel Aviv University.Aitor Aguirre, PhD, Associate Professor of Biomedical Engineering, Institute for Quantitative Health Science and Engineering, Chief, Division of Developmental and Stem Cell Biology (IQ), Director, MSU Stem Cell Core, Michigan State University.Ying Sun, PhD, Professor, Cincinnati Children's Hospital Medical Center, University of Cincinnati.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Mia Horowitz, PhDDr. Horowitz has no relevant financial relationships to disclose.Aitor Aguirre, PhDDr. Aguirre has no relevant financial relationships to disclose.Ying Sun, PhDDr. Sun receives research support from Enkefalos Biosciences and Yuhan Corporation.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Mi-décembre 2025, la Commission européenne a proposé de revenir sur l'interdiction de vente de véhicules neufs à moteur thermique après 2035. [Cette émission est une rediffusion de nos programmes] Pour simplifier les procédures et alléger les normes, différents amendements au pacte vert ont déjà été adoptés suite à un vote conjoint des députés du Parti Populaire Européen et de ceux des groupes d'extrême-droite.  À lire aussiUE: qu'est-ce que le Pacte Vert, enjeu des élections européennes?   En Albanie, la Vjosa et son parc national sont à nouveau menacés Les énergies fossiles et les activités industrielles accélèrent le réchauffement du climat, et détruisent aussi directement de nombreux écosystèmes, là où la réglementation est peu contraignante, ou peu appliquée. Il y a deux ans, le gouvernement albanais inaugurait le premier Parc National de rivière sauvage en Europe. Une victoire pour les écologistes qui luttaient depuis plus de 10 ans pour protéger la Vjosa, un fleuve à la biodiversité exceptionnelle. Mais deux ans et demi plus tard, la survie de cet espace naturel est à nouveau menacée, comme l'a constaté Louis Seiller sur les bords du fleuve, dans le sud de l'Albanie.  Le lac Balaton, en Hongrie, est lui aussi en danger Les Hongrois le surnomment la « mer du peuple », c'est le plus grand lac d'Europe, et un lieu de tourisme balnéaire très prisé. Mais son niveau d'eau est désormais très bas, car il subit de plein fouet les effets du changement du climat - des effets visibles à l'œil nu. Les précisions de Florence Labruyère. La chronique musique de Vincent Théval : Prince of Assyria Mach Cha Zamara  Voyage au pays du «çay» Avec une consommation d'environ  quatre kilos par personne et par an... C'est en Turquie, pays aux confluents de l'Europe et de l'Asie, que l'on boit le plus de thé au monde. Même si les Turcs ont adopté cette boisson assez récemment, elle est devenue incontournable dans leur vie sociale, mais aussi commerciale, politique... Partout, à toute occasion, dans les maisons, les magasins, les cafés, on boit du thé noir du matin au soir. À tel point que la production locale – pourtant au cinquième rang mondial – suffit tout juste à satisfaire les besoins du pays. À Ankara, Anne Andlauer. À lire aussiL'Union européenne renonce au tout-électrique en 2035 et autorise une part limitée de voitures thermiques

Shunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's Health, Delaware, USA; Alessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research Hospital, Tennessee, USA; Merve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical Center, Texas, USA; and Ryan Colburn, patient with Pompe disease and president of Odimm Inc, discuss new and emerging gene therapies for lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session6-current-issues-in-gene-therapies-for-lysosomal-disorders/  Learning ObjectivesDescribe current and emerging gene therapy data in lysosomal disorders and its clinical relevanceDescribe role of patients in gene therapy developmentFacultyShunji Tomatsu, MD, PhD, Professor and Head, Nemours Children's HealthAlessandra d'Azzo, PhD, Emerita Faculty, Genetics, St. Jude Children's Research HospitalMerve Emecen Sanli, MD, Associate Professor, Department of Pediatrics, University of Texas Southwestern Medical CenterRyan Colburn. Odimm, Inc.DisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Shunji Tomatsu, MD, PhD Dr. Tomatsu has received the following grants: Morquio Foundations and families: Scarlett Grifith, Bennett, A Cure for Roberts, and Morquio Conference; MPS Societies: Japanese, National, and Austrian; NIH grants: 1-R01-HD102545, NIH, NICHD, Tomatsu (PI), 1R01HD104814-01A1, NIH, NICHD, Langan, T.J. (PI), Role: Site-PI, R43HD114328-01, NIH, ACOSTA, WALTER (PI), Role: site PI, 1R43AR084638-01, NIH, MOUNZIH, KHALID (PI); Foundation of NIH: FNIH RFP NUMBER: 2022-BGTC-005 Tomatsu (PI). Alessandra d'Azzo, PhDDr. D'Azzo has no relevant financial relationships to disclose.Merve Emecen Sanli, MDDr. Sanli has no relevant financial relationships to disclose.Ryan ColburnMr. Colburn has an advisory, consulting and/or project based relationship or stock holding with: Abeona Therapeutics, Amicus Therapeutics, Astellas Gene Therapies, Avidity Biosciences, Bayer, Catalyst Pharmaceuticals, Denali Therapeutics, M6P Therapeutics, Sangamo Therapeutics, Sanofi, Solid Biosciences.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Oral Alpan, MD, Immunologist, Amerimmune, Virginia, USA; Svenja Keller, PhD student, University of Zurich, Switzerland; Shoshana Revel-Vilk, MD, PhD, Director, Gaucher Unit & Pediatric Hematology/Oncology Unit, Shaare Zedek Medical Center, Jerusalem, Israel; Patrick Deegan, MD, Consultant Metabolic Physician, University of Cambridge, UK; and Ravi Kamath, MD, PhD, Head of Musculoskeletal Radiology, Inova Health System, Virginia, USA, discuss the applications of AI in the diagnosis and treatment of lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session4-expanded-applications-of-ai-in-lysosomal-disorders/Learning ObjectivesDescribe how emerging AI and machine learning technologies are advancing disease modeling and biomarker development.Describe how emerging AI and machine learning technologies are advancing therapeutic target identification across lysosomal disorders.FacultyOral Alpan, MD, Immunologist, AmerimmuneSvenja Keller, PhD student, University of ZurichShoshana Revel-Vilk, MD, PhD, Director, Gaucher Unit & Pediatric Hematology/Oncology Unit, Shaare Zedek Medical CenterPatrick Deegan, MD, Consultant Metabolic Physician, University of CambridgeRavi Kamath, MD, PhD, Head of Musculoskeletal Radiology, Inova Health SystemDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Oral Alpan, MD Dr. Alpan has no relevant financial relationships to disclose.Svenja KellerMs. Keller has no relevant financial relationships to disclose.Shoshana Revel-Vilk, MD, PhDDr. Revel-Vilk receives grant/research support from Sanofi and Takeda. She is a member of the Speakers Bureau for Sanofi and Takeda, and a member of the Advisory Board for Takeda.Patrick Deegan, MDDr. Deegan is a consultant and advisory board member with Sanofi, Takeda, and Amicus.He also receives research support from Sanofi and Amicus.Ravi Kamath, MD, PhDDr. Kamath is on an advisory board for Intrinsic Therapeutics. He is also a consultant forSanofi, Takeda, and Spur Therapeutics.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Duarte C. Barral, PhD, Associate Professor, NOVA Medical School, NOVA University of Lisbon, Portugal; Nuno Raimundo, PhD, Associate Professor, Department of Cellular and Molecular Physiology; Penn State College of Medicine, Pennsylvania, USA; Betul Celik, PhD, Postdoctoral Fellow, Nemours Children's Health, Delaware, USA; and Gregory Newby, PhD, Assistant Professor, Department of Genetic Medicine, Johns Hopkins School of Medicine, Maryland, USA,discuss the principles of theranostics and its application in lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, please visit https://checkrare.com/learning/p-grids2025-session5-theranostics-and-lysosomal-disorders/ Learning ObjectivesDescribe lysosomal and inter-organelle mechanisms that contribute to pathology in lysosomal disorders, and how these pathways are being leveraged for diagnostic and therapeutic applications.Describe current and emerging theranostic strategies for lysosomal disorders.FacultyDuarte C. Barral, PhD, Associate Professor, NOVA Medical School, NOVA University of Lisbon, Nuno Raimundo, PhD, Associate Professor, Department of Cellular and Molecular Physiology; Penn State College of MedicineBetul Celik, PhD, Postdoctoral Fellow, Nemours Children's HealthGregory Newby, PhD, Assistant Professor, Department of Genetic Medicine, Johns Hopkins School of MedicineDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Duarte C. Barral, PhD Dr. Barral's group receives grant support from Sea4Us.Nuno Raimundo, PhDDr. Raimundo has no relevant financial relationships to disclose.Betul Celik, PhDDr. Celik has no relevant financial relationships to disclose.Gregory Newby, PhDDr. Newby has no relevant financial relationships to disclose.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Stephan Stern, PhD, DABT, Director of Research and Development, Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer Research, Maryland, USA; and Ruben Boado, PhD, Professor of Medicine, University of California at Los Angeles, California, USA, discuss the use of nanotechnology in the treatment of lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session2-nanotechnology-and-lysosomal-disorders/Learning ObjectivesDescribe recent advances in the use of nanotechnology to treat lysosomal disordersDescribe the role of nanotechnology in addressing unmet needs in lysosomal disordersFacultyStephan Stern, PhD, DABTDirector of Research and Development, Nanotechnology Characterization Lab (NCL), Frederick National Laboratory for Cancer ResearchRuben Boado, PhDProfessor of Medicine, University of California at Los AngelesDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Stephan Stern, PhD, DABTDr. Stern has no relevant financial relationships to disclose. Ruben Boado, PhDDr. Boado has no relevant financial relationships to disclose.Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Behzad Najafian, MD, Professor, Department of Laboratory Medicine & Pathology, Department of Medicine at the University of Washington, Washington, USA discusses the use of artificial intelligence in identifying and managing lysosomal disorders.This continuing education activity is provided through collaboration between the Lysosomal and Rare Disorders Research and Treatment Center (LDRTC), CheckRare CE, and AffinityCE. This activity provides continuing education credit for physicians, physician assistants, nurses, nurse practitioners, and genetic counselors. A statement of participation is available to other attendees.To obtain CME/CE credit, visit https://checkrare.com/learning/p-grids2025-session1-ai-in-medicine-transforming-the-landscape-of-tissue-based-diagnostics/Learning ObjectivesDescribe recent advances in the applications of AI in lysosomal disorder diagnosis and its clinical relevanceFacultyBehzad Najafian, MD Professor, Department of Laboratory Medicine & Pathology, Department of Medicine, University of WashingtonDisclosuresAffinityCE staff, LDRTC staff, planners, and reviewers, have no relevant financial relationships with ineligible companies to disclose. Faculty disclosures, listed below, will also be disclosed at the beginning of the Program.Behzad Najafian, MDDr. Najafian is on the Advisory Board/Consultant for Sanofi, Amicus, Avrobio, 4DMT,Sangamo, Freeline, AceLink, Relay, CRISPR, ELOXX, SPARK, UNIQURE. He receives grants/research support from Amicus. Mitigation of Relevant Financial RelationshipsAffinityCE adheres to the ACCME's Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CME activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of the activity. Conflicts of interest for presenting faculty with relevant financial interests were resolved through peer review of content by a non-conflicted reviewer.Accreditation and Credit DesignationPhysiciansThis activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of AffinityCE and the LDRTC. AffinityCE is accredited by the ACCME to provide continuing medical education for physicians.AffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.Physician AssistantsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Physician Assistants should claim only the credit commensurate with the extent of their participation in the activity.NursesAffinityCE is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation (ANCC). This activity provides a maximum of 1 hours of continuing nursing education credit.Nurse PractitionersAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Nurse practitioners should claim only the credit commensurate with the extent of their participation in the activity.Genetic CounselorsAffinityCE designates this enduring activity for a maximum of 1 AMA PRA Category 1 Credits™. Genetic Counselors should claim only the credit commensurate with the extent of their participation in the activity.Other ProfessionalsAll other health care professionals completing this continuing education activity will be issued a statement of participation indicating the number of hours of continuing education credit. This may be used for professional education CE credit. Please consult your accrediting organization or licensing board for their acceptance of this CE activity. Participation CostsThere is no cost to participate in this activity.CME InquiriesFor all CME policy-related inquiries, please contact us at ce@affinityced.comSend customer support requests to cds_support+ldrtc@affinityced.com

Mi-décembre 2025, la Commission européenne a proposé de revenir sur l'interdiction de vente de véhicules neufs à moteur thermique après 2035. [Cette émission est une rediffusion de nos programmes] Pour simplifier les procédures et alléger les normes, différents amendements au pacte vert ont déjà été adoptés suite à un vote conjoint des députés du Parti Populaire Européen et de ceux des groupes d'extrême-droite.  À lire aussiUE: qu'est-ce que le Pacte Vert, enjeu des élections européennes?   En Albanie, la Vjosa et son parc national sont à nouveau menacés Les énergies fossiles et les activités industrielles accélèrent le réchauffement du climat, et détruisent aussi directement de nombreux écosystèmes, là où la réglementation est peu contraignante, ou peu appliquée. Il y a deux ans, le gouvernement albanais inaugurait le premier Parc National de rivière sauvage en Europe. Une victoire pour les écologistes qui luttaient depuis plus de 10 ans pour protéger la Vjosa, un fleuve à la biodiversité exceptionnelle. Mais deux ans et demi plus tard, la survie de cet espace naturel est à nouveau menacée, comme l'a constaté Louis Seiller sur les bords du fleuve, dans le sud de l'Albanie.  Le lac Balaton, en Hongrie, est lui aussi en danger Les Hongrois le surnomment la « mer du peuple », c'est le plus grand lac d'Europe, et un lieu de tourisme balnéaire très prisé. Mais son niveau d'eau est désormais très bas, car il subit de plein fouet les effets du changement du climat - des effets visibles à l'œil nu. Les précisions de Florence Labruyère. La chronique musique de Vincent Théval : Prince of Assyria Mach Cha Zamara  Voyage au pays du «çay» Avec une consommation d'environ  quatre kilos par personne et par an... C'est en Turquie, pays aux confluents de l'Europe et de l'Asie, que l'on boit le plus de thé au monde. Même si les Turcs ont adopté cette boisson assez récemment, elle est devenue incontournable dans leur vie sociale, mais aussi commerciale, politique... Partout, à toute occasion, dans les maisons, les magasins, les cafés, on boit du thé noir du matin au soir. À tel point que la production locale – pourtant au cinquième rang mondial – suffit tout juste à satisfaire les besoins du pays. À Ankara, Anne Andlauer. À lire aussiL'Union européenne renonce au tout-électrique en 2035 et autorise une part limitée de voitures thermiques

Here's a question that keeps salespeople up at night: How do you ask for more compensation when you're getting competitive external job offers without sounding like you're issuing an ultimatum? That's the question posed by Brady from Arkansas. Brady's been getting legitimate job offers from recruiters, and he's wondering how to leverage these opportunities into better compensation at his current company without burning bridges or coming across as disloyal. If you've ever found yourself in this position, you know it's a delicate dance. You want to be paid what you're worth, but you also don't want to destroy the relationships and goodwill you've built. So how do you navigate this conversation? The Right Way to Have the Conversation If you're getting external job offers from legitimate companies with strong brands, the key is in how you frame the conversation with your boss. Here's the approach: "I really like working here, and I want to stay at this company. I love it. But I've got another company out there that's a good company. They're a great brand, they're well known, and they're making this job offer to me at a significantly higher level of compensation. It's hard for me to say no to that. I feel like I need to bring this to you before I make a decision because I like working here." Notice what you're NOT saying. You're not walking in with an ultimatum saying, "If you don't give me this, I'm leaving." Instead, you're saying, "I want to stay here. I like it here. I'm just in a situation where they're offering me enough that it's turning my head and I'm looking their way." This approach keeps the door open for a productive conversation about what might be possible without threatening your current employer or damaging your relationship. When Loyalty Actually Matters Now, before you go schedule that meeting with your boss, you need to ask yourself a hard question: Do you owe this company some loyalty? If you were down on your luck, lost a job, and they came along and gave you something that saved you, you probably owe them some loyalty for that. Not forever, but there's a little bit of honor in not just jumping to the next place immediately. You also need to think about your resume. If you've just got there and a year later you're jumping to another place, that's on your resume. And believe it or not, even in today's world, that still means something. I won't hire people who jump from job to job every year. I don't care how good they are because they're probably going to jump again. So think long term: Am I demonstrating to a future employer that I'm worth investing more money in? The answer is yes when you gave them three years of your life, performed at a really high level, and now you're going to leverage that to go level up elsewhere. Speaking Your Boss's Language Here's what most salespeople get wrong when asking for more money: They forget to speak the language their boss understands. If you walk into your sales leader's office and say, "I want to make more money," you know what they're going to tell you? "Go sell more." And they're right. If you've got a great compensation plan with no limit on how much commission you can make, the answer is simple: crank out more sales. So before you ask for more base salary, ask yourself: Do I have a limit on how much commission I can make? If the answer is no, then your first conversation should be about getting bigger opportunities. Try this approach: "I can sell. I'm hitting numbers, but I'm not making the money I want. What can you do to give me bigger accounts, bigger opportunities, bigger customers? Give me better leads. What can you do to get me in a situation where I can earn more?" This is speaking the boss's language. You're showing that you want to produce more, not just get paid more for the same work. If you get shut down in that situation, then you have another conversation. The Commission vs. Base Salary Play If you're a baller and you've proven you can sell, here's a move most salespeople never consider when negotiating compensation: Ask for a higher commission percentage instead of a higher base salary. I honestly don't care about base. I think a base matters when you're getting started, and it's nice to have, but I would much rather have a higher commission percentage than a higher base. Here's how you position it: "In the open market, I can take a similar job and make $400,000. I want to make the same thing here. Now there's two ways we could do this. One is that you can increase my base salary. Two is you give me a higher commission rate, and I think the commission rate should be this. I think I'm worth that." What you're basically saying is that your cost of sales is going to be variable. They only pay you if you sell it, so their carrying costs stay the same. In my company, the people who don't take a base salary make more than double in commission what people who do take a base salary bring home. There's a massive difference because the people saying "pay me more commission" are saying "I'm willing to put skin in the game in order to make more." Now, this doesn't work if you're at a massive company with a thousand salespeople and rigid HR policies. But if you work for a smaller organization where people can make decisions, have an honest conversation around this approach. You might even propose a tiered structure: "You can pay me your base commission on everything up to the quota you gave me. But once I cross that quota, I want my commission to roll up so that if I get over this number, the rate scales." That's a conversation most entrepreneurial leaders will entertain because it's putting your money where your mouth is. What Money Can't Buy Here's the thing most people miss when they're chasing the next big paycheck: There's always money out there you can chase. You have an obligation to yourself and your family to make as much as you possibly can in sales. But there's also the value of working in a place that values you. There's more than just the money. There's the freedom, the flexibility, and the opportunity to be part of something that gives you purpose. I had somebody come to me recently and ask this question, and I said, "This job that you're moving to that's going to pay you all this money, suddenly you're going to have someone who's micromanaging and telling you what to do every single day. In your current role, you're not making as much money, but you call the shots on your day every single day. Nobody even messes with you. Are you willing to sign up for that?" They said their wife told them the exact same thing. Maybe that's a sign that having the freedom and flexibility is more valuable than making a lot of money but being miserable because everything you do is being micromanaged. The Bottom Line When it's time to ask for more money, remember these principles: Bring the conversation to your boss before making a decision. Frame it as wanting to stay, not threatening to leave. Consider what you owe in loyalty. If they gave you a chance when you needed one, factor that into your decision. Speak your boss's language. Ask for bigger opportunities before asking for more base pay. Consider the commission play. If you're confident in your abilities, asking for higher commission rates can be more lucrative than base salary increases when looking at total compensation. Weigh the intangibles. Money isn't everything if you're trading freedom and fulfillment for a micromanaged existence. The best compensation conversations happen when you approach them with confidence, gratitude, and a clear understanding of your value. That's how you get paid what you're worth without burning bridges along the way. Want to learn more about leveraging your personal brand to create more career opportunities? Check out Jeb's newest book, The LinkedIn Edge, and discover how to turn your LinkedIn profile into a powerful career and sales tool.

In this episode of The China Desk, host Steve Yates speaks with US-China Economic and Security Review Commission members Randy Schriver and Mike Kuiken about the Commission's latest annual report to Congress. The conversation breaks down China's rapid advances in space as a warfighting domain, quantum computing and encryption threats, biotechnology competition, and deep vulnerabilities in U.S. supply chains. Drawing on decades of national security experience, the guests explain why technological literacy, allied coordination, and long-term investment are now critical to maintaining U.S. and allied security in the Indo-Pacific. Watch Full-Length Interviews: https://www.youtube.com/@ChinaDeskFNW

With the new season just a month away and the new year ringing in this week, Jake, Safe, and Ryan turn their attention to 2026 with a New Year's Resolution for some teams, some 2026 lacrosse predictions, and a look back at some of our favorite things in 2025.The 2026 season's fast approaching, so subscribe to The Crosse Commission on YouTube to get yourself ready for our exclusive live streams coming up around the bend! 

EDITORIAL: Independent People's Commission: Right idea, wrong execution | Dec. 31, 2025Subscribe to The Manila Times Channel - https://tmt.ph/YTSubscribeVisit our website at [https://www.manilatimes.net](https://www.manilatimes.net/)Follow us:Facebook - https://tmt.ph/facebookInstagram - https://tmt.ph/instagramTwitter - https://tmt.ph/twitterDailyMotion - https://tmt.ph/dailymotionSubscribe to our Digital Edition - https://tmt.ph/digitalCheck out our Podcasts:Spotify - https://tmt.ph/spotifyApple Podcasts - https://tmt.ph/applepodcastsAmazon Music - https://tmt.ph/amazonmusicDeezer: https://tmt.ph/deezerStitcher: https://tmt.ph/stitcherTune In: https://tmt.ph/tunein#TheManilaTimes#VoiceOfTheTimes Hosted on Acast. See acast.com/privacy for more information.

C'est le dernier épisode d'un long feuilleton juridico-commercial vieux de plus d'une décennie. Le Parlement européen a adopté de justesse, le 26 novembre, un nouvel accord commercial sur la pêche et l'agriculture entre l'UE et le Maroc. Après l'annulation du précédent texte datant de 2019, les indépendantistes du Front Polisario demandaient que les produits issus du Sahara occidental en soient exclus, mais ce ne sera finalement pas le cas. De notre correspondant à Casablanca, La nouvelle version de l'accord agricole Rabat-Bruxelles comprend bien les produits du Sahara occidental. Des tomates, essentiellement, et des melons qui poussent, hors sol, sous d'immenses serres. Ils continueront de bénéficier d'une réduction des droits de douane. « Au final, le Maroc demeure le principal bénéficiaire puisqu'il obtient une reconnaissance pratique de la continuité des préférences accordées à ses exportations, y compris celles provenant des provinces du Sud », détaille Zaher Badr Al Azrak, professeur de droit des affaires à l'université Hassan II de Casablanca. « Provinces du Sud », c'est l'expression utilisée au Maroc pour désigner ces territoires revendiqués par le Front Polisario. Le nouveau texte amendé par la Commission européenne propose une formulation juridique inédite, pour respecter l'arrêt de la Cour de justice de l'UE. « Le changement ne porte pas sur la substance même de l'accord commercial, mais plutôt sur sa mise en œuvre. Les Européens ont introduit des mécanismes pratiques et techniques », poursuit-il. Une concurrence déloyale ? À l'exigence de traçabilité de la Cour, Bruxelles répond par un étiquetage spécifique, mentionnant simplement les deux régions de production autour des villes de Dakhla et de Laâyoune. Le Front Polisario dénonce une disposition illégale. « En fait, il n'y a pas eu de grands changements. L'Union européenne et le Maroc ont repris pratiquement les mêmes dispositions. Ils les ont reconduites dans ce traité. Je pense que le Maroc a enregistré une victoire par rapport à ses détracteurs », souligne l'analyste économique et politique marocain, Driss Aïssaoui. Les échanges agricoles ne cessent de progresser entre le Maroc et l'UE. L'année dernière, ils ont atteint plus de 7 milliards d'euros. Ainsi, tout en annulant l'accord commercial en 2024, la Cour de justice de l'UE l'avait maintenu pour une durée transitoire de 12 mois. « L'Union européenne est un partenaire fort et indispensable, mais qui fonctionne selon des équilibres internes complexes, analyse Zaher Badr Al Azrak. C'est précisément pour cela que la diversification des partenariats en Afrique, en Asie ou en Amérique latine n'est plus une option secondaire, mais une nécessité stratégique pour le royaume. » Le texte tout juste adopté compte encore des ennemis : des syndicats agricoles français et espagnols qui dénoncent une concurrence déloyale. Le Front Polisario aussi, qui prévoit de saisir à nouveau la Cour de justice de l'Union européenne d'ici la fin du mois de décembre. À lire aussiLes produits du Sahara occidental inclus dans l'accord commercial Maroc-UE

Even with no regularly scheduled Commission meeting this week, Sedgwick County Commission Chairman Ryan Baty joins us with a look to next year on the county calendar.

Quelle sera la limite pour les prix de cuivre ? La question qui se posait déjà il y a un mois est encore plus d'actualité aujourd'hui. Le métal rouge a poursuivi son ascension ce mois de décembre pour dépasser les 12 000 dollars la tonne, et s'apprête à connaître sa plus forte hausse annuelle depuis 2009. La hausse des cours du cuivre de 40 % en un an est l'illustration d'une inquiétude, celle de voir l'approvisionnement rester perturbé par des incidents miniers comme ceux qui ont affecté la production de plusieurs gisements cette année au Chili, en République démocratique du Congo, ou encore en Indonésie - où la production du site de Blockcave, à Grasberg interrompue en septembre, ne devrait reprendre qu'au deuxième trimestre 2026. L'autre crainte, c'est l'instauration de nouvelles taxes américaines. Les droits de douane actuels imposés en août dernier ne visent pas tous les matériaux à base de cuivre. La possibilité de voir d'autres produits taxés, tels que les cathodes de cuivre par exemple, continue de soutenir les achats américains qui ont explosé de 30 % sur les huit premiers mois de l'année, selon Natixis. Les stocks du Comex, la bourse aux métaux de New York, dépassent désormais les 480 000 tonnes.  Si les États-Unis continuent d'acheter, cela fera moins de métal rouge pour les autres et notamment pour la Chine, le premier importateur mondial, qui a émis le souhait, via la Commission nationale du développement et de la réforme (CNDR), de mieux contrôler l'expansion de son industrie du cuivre d'ici 2030, par crainte d'être en surcapacité, alors que l'offre minière, c'est-à-dire le minerai brut disponible, ne devrait pas croître l'année prochaine de plus de 1 %. Des prix poussés par la faiblesse du dollar Le cuivre est souvent présenté comme un bon indicateur de l'activité industrielle et manifestement, les perspectives d'un soutien plus grand de Pékin à son économie sont suffisantes pour alimenter les cours à la hausse selon le cabinet SP Angel, cité par le Financial Times.  L'autre facteur à prendre en compte, c'est la faiblesse du dollar américain qui a un impact général sur les métaux précieux et les métaux de base : la plupart sont cotés en dollar, ce qui permet aux importateurs d'acheter plus en déboursant le même montant dans leur monnaie. Mécaniquement, la demande augmente et les prix avec.  Des prix qui devraient redescendre en 2026 En 2026, il faudra toujours plus de cuivre pour construire les réseaux électriques, et répondre aux besoins énergétiques suscités par le développement de l'intelligence artificielle. Là-dessus il n'y a guère de doute. Ce qui va conditionner l'évolution des prix, c'est à quelle vitesse ces besoins vont augmenter. La hausse actuelle des prix reflète l'anticipation de besoins importants. Les analystes ne sont cependant pas tous d'accord. Chez Natixis on anticipe une demande qui ne devrait pas évoluer drastiquement en 2026 en raison d'un environnement macro-économique relativement terne, mais qui pourrait rester « artificiellement » forte à cause des incitations américaines à l'importation. Natixis anticipe un déficit potentiellement sévère, avec des prix qui pourraient avoisiner les 11 000 dollars la tonne, alors que Goldman Sachs table sur un excédent, et anticipe un prix moyen du cuivre à la bourse aux métaux de Londres (LME) de 10 710 dollars au premier semestre 2026. À lire aussiLes prix du cuivre en augmentation de près de 25% cette année

Rien n'arrête Khalid Tamer, metteur en scène d'origine marocaine, premier président africain de la Commission internationale du théâtre francophone et directeur du théâtre le Lavoir Moderne Parisien. (Rediffusion du 20/08/2025) Khalid Tamer est un homme du terroir : « J'ai grandi en Corrèze, puis je suis monté à l'âge de 18 ans à Paris pour faire du théâtre ». Une passion qui ne l'a plus quitté. Il crée au cœur du quartier multiculturel de la Goutte d'Or dans le 18e arrondissement parisien un lieu unique, la compagnie Graines de Soleil - Lavoir Moderne Parisien. Un espace de création atypique : il s'agit tout simplement d'un ancien lavoir transformé en un lieu unique et expérimental où de jeunes troupes ont carte blanche. « On dit qu'Émile Zola en parle dans son roman L'Assommoir. Voyez, il y a encore là les traces qui sont présentes des bassines où les femmes lavaient leur linge. C'est un lieu qui a une belle histoire, ce sont des murs qui ont une âme. En 1986, cet espace est devenu un théâtre, où artistes, auteurs, et des militantes comme les Femen, un groupe de protestation féministe fondé en Ukraine en 2008, célèbres pour avoir organisé des manifestations seins nus, sont venues. Vous voyez le symbole ! Puis j'ai eu mon propre combat pendant six ans avec un des propriétaires qui voulait détruire ce lieu, donc on s'est battu pour le garder tel qu'il est avec tout son charme. » Et c'est toujours au Lavoir Moderne Parisien qu'il vient d'achever la 4ᵉ édition d'Africapitales, avec le Sénégal comme invité d'honneur. Faire venir l'Afrique et ses cultures à Paris, c'est l'un des défis de cet homme passionné de cultures. « Il y a quelque chose de très africain en moi, j'ai l'impression que je suis un nomade et partout où je suis, je porte ma maison », explique-t-il. Première rencontre Dans ce cocon artistique, Virginie Chevalier, Québécoise, l'a rejoint. Cette scénographe a travaillé sur de nombreux projets et pièces de théâtre montés par la compagnie Graines de Soleil aux côtés de Khalid, fascinée par cet homme qui partage sa vie. « Pour moi, Khalid est vraiment au service de la culture. On lui donne un billet d'avion, il te crée un festival dans le monde. Pour lui, l'art est au-dessus de tout. » Au Maroc où il est né, il a des projets. Et à Tanger, ses rêves deviennent réalité. Il vient d'acquérir l'emblématique librairie des Colonnes, c'est aussi dans cette ville, carrefour des cultures entre l'Europe et l'Afrique, qu'il a organisé la première édition des rencontres méditerranéennes de Tanger. Un événement culturel rendu possible avec Marc Bitton de la Fondation Founoun Al Boughaz - Arts du Détroit.  Ensemble, ils ont imaginé ce projet. Au menu : des concerts, des expositions et des débats au cœur de la kasbah… où le Liban et sa littérature étaient aussi à l'honneur. Funambule artistique « J'avais très envie qu'on soit présent parce que je pense qu'on a ce défaut dans notre partie du monde de vouloir toujours dialoguer à travers la France », souligne l'écrivaine Georgia Makhlouf. « Je dirais que c'est en France qu'on rencontre les écrivains venus du Maroc, d'Algérie ou de Tunisie… Donc, moi, j'aime beaucoup l'idée d'avoir enfin des liens directs afin d'apprendre à se connaître, je pense qu'on a beaucoup à partager, qu'on a beaucoup à apprendre pour arriver à faire des choses ensemble ». Khalid Tamer tisse des liens : « J'aime rencontrer l'autre que je ne connais pas et j'aime prendre des risques, c'est ma manière de vivre, je suis comme un funambule. » Un véritable funambule artistique qui avance d'un pas délicat et sûr, sans jamais s'arrêter de créer. À lire aussiDiasporas africaines en France: Dieudonné Mbeleg, un «Africain» à la tête de la prison de Nantes [2/5]

Au menu :00:00 Introduction et flash info 02:30 La chronique de Guy de la Fortelle

Le 19 juillet 1995 était signée, par Nelson Mandela, la loi qui créait la Commission vérité et réconciliation. Une expérience de justice restaurative pour tenter de panser les terribles plaies de l'apartheid. Une dynamique qui a créé des émules partout dans le monde. Mais aujourd'hui, le bilan est finalement assez mitigé, car les suspects qui n'ont pas obtenu d'amnistie n'ont jamais été inquiétés par les tribunaux. Le temps n'efface pas tout et désormais, les familles des victimes veulent des réponses.  « 30 ans plus tard, l'ombre des crimes de l'apartheid continue de planer sur l'Afrique du Sud », un Grand reportage signé Claire Bargelès et Valentin Hugues. [Rediffusion du 8 septembre 2025]

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

Welcome Online Family!  Join us in worshipping the King of Kings Jesus. If you have a need that we can pray for, please feel free to comment below or DM us and we would love pray with you! To support this ministry and help us continue to reach people all around the world click here: https://bit.ly/36vpxdD Subscribe to get notifications on all the latest sermons and worship covers, click on the bell icon to receive notifications every time we post! Share with your friends, colleagues, loved ones.  ------------------------------------------- Connect with us on all Commission Socials: https://linktr.ee/CommissionChurch

Low Co-operating Commission in Real Estate | How to Handle It as a Buyer's Agent

Welcome to The Daily, where we study the Bible verse by verse, chapter by chapter, every day. Read more about Project23 and partner with us as we teach every verse of the Bible on video. Our text today is Judges 19:1-3. This isn't just another story—it's a wake-up call. The Levite's failure reminds us how quickly spiritual leaders can drift from conviction to compromise. God is looking for men and women who will not only know His Word but live it, defend it, and pass it on with courage. In those days, when there was no king in Israel, a certain Levite was sojourning in the remote parts of the hill country of Ephraim, who took to himself a concubine from Bethlehem in Judah. And his concubine was unfaithful to him, and she went away from him to her father's house at Bethlehem in Judah, and was there some four months. Then her husband arose and went after her, to speak kindly to her and bring her back. He had with him his servant and a couple of donkeys. And she brought him into her father's house. And when the girl's father saw him, he came with joy to meet him. — Judges 19:1-3 By the time we reach Judges 19, Israel has plunged to its lowest point. Even the Levites—men once set apart to teach and guard God's law—no longer remember it. The opening line says it all: "There was no king in Israel." In other words, there was no authority, no truth, no standard—only self-rule. Here stands a Levite, a man supposed to model holiness. Instead, he takes a concubine—a live-in girlfriend with marital benefits but no covenant commitment. She betrays him, runs home, and after months apart, he decides he wants her back. The relationship is dysfunctional from every direction. But the greater tragedy is this: a priest who should lead God's people can't even lead himself. That's the climate of moral collapse—when spiritual leaders trade holiness for cultural conventions, then the nation no longer knows what righteousness looks like. We live in the same era of moral relativism—everyone doing what seems right in their own eyes. Churches ordain what God calls sin. Pulpits preach self-esteem instead of repentance. Pastors chase applause over truth. But notice they still wear the robes, carry the titles, build buildings, and quote a few verses—but like this Levite, they've abandoned the covenant. And the result? Confused believers. Compromised faith. A generation that can no longer tell the difference between God's truth and cultural tolerance. We've come a long way from Joshua's bold declaration—"As for me and my house, we will serve the Lord." Now we say, "As for me and the truth, we'll do what feels right." When leaders forget the Word, the people follow their feelings. And when that happens, nations collapse from the inside long before enemies ever invade. The Levite's story isn't just a scandal—it's a warning shot and a challenge. When God's people drift from His Word, it's not enough to simply shake our heads—we must act. Step up where he stepped back. Lead where he lacked courage. Recommit to Scripture in your home, your marriage, your circle of influence. Because when we return to God's Word, broken relationships can be healed, leadership restored, and love redeemed. ASK THIS: Where have you seen "moral relativism" creep into the church? Have you traded biblical truth for cultural comfort in any area of life? What voices in your life hold you accountable to Scripture? How can you encourage your pastor—or yourself—to stand firm on truth this week? DO THIS: Pray daily for pastors and leaders to preach truth with courage and clarity. Recommit to reading Scripture before social media or news; make God's Word your authority again. PRAY THIS: Lord, reignite conviction in Your people. Make us builders of truth and defenders of faith. Give us courage to lead boldly where others have drifted, and help us restore what weak leadership has lost. Commission us to act—not just believe—so that Your Word defines every choice we make. Amen. PLAY THIS: "Come to the Altar."

Caribbean CIPs should tighten vetting “pending discontinuation of those schemes,” reads a recent report by the EU Commission. View the full article here.Subscribe to the IMI Daily newsletter here. 

"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer.  Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article:  A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14  "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01

L'année 2025 restera comme une année charnière pour l'économie mondiale, marquée par le retour tonitruant de Donald Trump à la Maison-Blanche et ses décisions commerciales radicales. Cette émission spéciale d'Éco d'ici, éco d'ailleurs revisite, avec les experts qui sont intervenus à notre micro, les moments clés d'une année économique tumultueuse, entre guerres commerciales, crises géopolitiques, révolution de l'intelligence artificielle et urgence climatique.  

durée : 00:24:26 - L'invité de 8h20 - Le député LFI de Seine-Saint-Denis, Éric Coquerel, également président de la Commission des finances, est l'invité de France Inter. Il explique pourquoi son groupe ne votera pas le budget. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

L'année 2025 restera comme une année charnière pour l'économie mondiale, marquée par le retour tonitruant de Donald Trump à la Maison-Blanche et ses décisions commerciales radicales. Cette émission spéciale d'Éco d'ici, éco d'ailleurs revisite, avec les experts qui sont intervenus à notre micro, les moments clés d'une année économique tumultueuse, entre guerres commerciales, crises géopolitiques, révolution de l'intelligence artificielle et urgence climatique.  

After decades of exceptional leadership at the Washington Red Raspberry Commission, Henry Bierlink stepped aside last summer, making his way into a well-deserved retirement.

Retired FBI agent Michael Clarke and retired DEA agent Jack McFarland review their 2004 joint FBI and DEA investigation of "The Commission," a violent criminal gang operating in the U.S. Virgin Islands which includes St. Thomas, St. John, and St. Croix, whose members were convicted in federal court for racketeering, murder, and drug trafficking. The case was conducted under the Organized Crime Drug Enforcement Task Force (OCDETF) program, the Safe Streets Task Force initiative, and the High Intensity Drug Trafficking Area (HIDTA) program. Mike and Jack both served as agents for 32 years.    Check out episode show notes, photos, and related articles: https://jerriwilliams.com/382-michael-clarke-and-jack-mcfarland-disrupting-the-commission-us-virgin-islands/     Join my Reader Team to get the FBI Reading Resource - Books about the FBI, written by FBI agents, the 20 clichés about the FBI Reality Checklist, and keep up to date on the FBI in books, TV, and movies via my monthly email. Join here. http://eepurl.com/dzCCmL  Buy me a coffee - https://www.buymeacoffee.com/JerriWilliams   Check out my FBI books, non-fiction and crime fiction, available as audiobooks, ebooks and paperbacks wherever books are sold. https://jerriwilliams.com/books/

Les accords de paix signés en 2016 entre le gouvernement colombien et les FARC ont ouvert une nouvelle phase du conflit armé. Aujourd'hui encore, il y a des groupes armés actifs dans le pays. Ils constituent une menace directe pour les populations LGBTQI+, déjà durement éprouvées avant le processus de paix par des décennies de violences sexuelles, de menaces, de disparitions forcées et d'assassinats ciblés. Un dossier de Sarah Krakovitch.   Les groupes armés imposent des normes de genre strictes dans les territoires qu'ils contrôlent et font des personnes LGBTQI+ des cibles privilégiées de la violence. Selon l'International Crisis Group, les guérillas exploitent la vulnérabilité des minorités de genre pour asseoir leur domination territoriale, multipliant agressions, menaces et violences marquées par des préjugés transphobes. Depuis les accords de paix de 2016, la fragmentation des groupes armés a accru l'insécurité : les règles changent selon les zones et les chefs locaux, rendant toute stratégie de protection quasi impossible pour les populations LGBTQI+. Cette insécurité est palpable grâce au témoignage de Gabriela, une militante transgenre colombienne contrainte de déménager à plusieurs reprises après avoir reçu des menaces liées à son engagement. Selon l'ONG Caribe Afirmativo, 164 personnes LGBTQI+ ont été assassinées en Colombie en 2024, soit presque une tous les deux jours depuis 2023. Comment partager l'eau entre les Etats-Unis et le Mexique ? C'est l'histoire de deux voisins. D'un côté le Mexique, de l'autre les Etats-Unis. Pour arroser leurs jardins respectifs, ils se partagent des tuyaux depuis 80 ans. Mais depuis, des sécheresses sont passés par là...  les débit se sont réduits... Et le partage n'est plus équitable...Ce qui a poussé Donald Trump à dépoussiérer ce vieux traité de 1944 sur le partage de l'eau. Il reproche à México de ne plus en respecter les obligations. Depuis le Mexique s'est engagé à verser 246 millions de mètre cubes d'eau de l'autre côté de la frontière. Mais en est-il vraiment capable ? D'ailleurs est-il vraiment coupable de cette situation ? Le nouvel accord signé le 13 décembre dernier sera-t-il durable ? Joris Zylberman en parle avec le spécialiste de l'Amérique latine Jean-Louis Martin, chercheur à l'Institut français des relations internationales. Arrestations de plus en plus filmés, l'offensive médiatique de l'ICE L'ICE, l'agence fédérale chargée de l'immigration, s'est lancée dans une véritable offensive médiatique. Les vidéos montrant des arrestations musclées de migrants se multiplient sur les réseaux sociaux. Et c'est une stratégie pleinement assumée, selon le Washington Post, qui a eu accès à des milliers de messages internes de l'agence. Ces échanges montrent comment l'ICE produit et diffuse massivement ces clips, souvent filmés de manière spectaculaire, afin de répondre aux attentes de la Maison-Blanche. L'objectif est clair : montrer une action musclée, valoriser les expulsions et présenter la politique migratoire comme une bataille pour protéger le mode de vie américain. Le reportage révèle la transformation profonde du service de communication de l'ICE, devenu, sous le second mandat de Donald Trump, une véritable machine médiatique. Les vidéos sont soigneusement mises en scène : choix des images, du vocabulaire, de la musique, tout est pensé pour maximiser le partage et la viralité. Les échanges internes révèlent aussi des propos moqueurs, parfois déshumanisants, et une logique assumée de propagande, en rupture avec la communication plus neutre des administrations précédentes. Mais malgré cette offensive numérique sans précédent, le Washington Post souligne que l'impact sur l'opinion publique reste limité : une majorité d'Américains continue de voir l'immigration comme une richesse et désapprouve la gestion de Donald Trump. Journal d'Outre-mer la 1ère La compagnie aérienne Corsair a reçu le feu vert de la Commission européenne pour son plan de restructuration.

Les journalistes et experts de RFI répondent également à vos questions sur l'expulsion de Kényans en Afrique du Sud, une photo de Donald Trump supprimée des dossiers de l'affaire Epstein et l'alliance Iran/Venezuela contre les États-Unis. Mercosur-UE : l'impossible signature ?  Alors que près de 7 300 agriculteurs européens ont manifesté leur colère contre l'accord UE-Mercosur, la présidente de la Commission européenne, Ursula von der Leyen, a annoncé un report de la signature de l'accord. Pourquoi la France est-elle autant opposée à cet accord commercial ? Une signature est-elle possible sans Paris ? Avec Stéphane Geneste, journaliste au service économie de RFI, présente la chronique « Aujourd'hui l'économie ».      Afrique du Sud : pourquoi l'expulsion de sept Kényans irrite Washington ?  L'Afrique du Sud a expulsé sept ressortissants kényans accusés de travailler illégalement pour un programme américain de relocalisation des Afrikaners. Comment les Américains justifient-ils la présence de ces Kényans sur le territoire sud-africain ? Cela fait plusieurs mois que Washington accuse Pretoria de persécuter les Afrikaners. Sur quels éléments reposent ces accusations ? Avec Liza Fabbian, journaliste au service Afrique de RFI.      Affaire Epstein : Trump à nouveau au cœur des interrogations   La récente publication des archives judiciaires de l'affaire Jeffrey Epstein aux États-Unis a été marquée par la mystérieuse disparition du fichier n°468 et d'une quinzaine d'autres documents, dont une photo associant le président Donald Trump à Epstein. Pourquoi cette photo a-t-elle été effacée ? Le département de justice pourrait-il être influencé par Donald Trump ? Avec Jérôme Viala-Gaudefroy, docteur en civilisation américaine, spécialiste en rhétorique présidentielle.       Iran-Venezuela : alliés face aux ingérences américaines ?  L'Iran a proposé son aide au Venezuela dans le bras de fer qui l'oppose aux États-Unis, dénonçant les sanctions américaines et affirmant sa solidarité avec Caracas.  Pourquoi Téhéran propose-t-il son soutien à Caracas ? Quelle forme pourrait prendre cette coopération ? Avec Pascal Drouhaud, président de l'association LatFran, spécialiste de l'Amérique latine.

durée : 00:39:02 - Questions du soir : le débat - par : Antoine Dhulster, Louise Cognard - Le 18 décembre dernier, Ursula Von der Leyen a annoncé reporter d'un mois la signature de l'accord de libre-échange avec le Mercosur. Sur fond de désaccords autour de l'agriculture, les tergiversations européennes ne risquent-elles pas de profiter à la Chine, autre partenaire de choix du Mercosur ? - réalisation : Margot Page - invités : Mathilde Dupré Économiste, co-directrice de l'Institut Veblen; Alain Guillemoles Journaliste en charge de l'Union européenne à La Croix; Jean-Luc Demarty Ancien directeur général du Commerce et de l'Agriculture à la Commission européenne

Send us a textIn this episode, Pastor Dom teaches us to ponder on the Word of God like Mary did. Luke 1:26-2826 Now in the sixth month the angel Gabriel was sent by God to a city of Galilee named Nazareth, 27 to a virgin betrothed to a man whose name was Joseph, of the house of David. The virgin's name was Mary. 28 And having come in, the angel said to her, “Rejoice, highly favored one, the Lord is with you; blessed are you among women!”Luke 1:2929 But she was very perplexed at this statement, and was pondering what kind of greeting this was.Luke 11:27-2827 And it happened, as He spoke these things, that a certain woman from the crowd raised her voice and said to Him, “Blessed is the womb that bore You, and the breasts which nursed You!” 28 But He said, “More than that, blessed are those who hear the word of God and keep it!”Luke 2:1919 But Mary kept all these things and pondered them in her heart.Luke 1:3838 Then Mary said, “Behold the maidservant of the Lord! Let it be to me according to your word.” And the angel departed from her.2 Timothy 3:1616 All Scripture is given by inspiration of God, and is profitable for doctrine, for reproof, for correction, for instruction in righteousness,Proverbs 23:7For as he thinks in his heart, so is he.Matthew 12:3434 …For out of the abundance of the heart the mouth speaks.2 Corinthians 5:1717 Therefore, if anyone is in Christ, he is a new creation; old things have passed away; behold, all things have become new.Psalm 56:1111 In God I have put my trust;I will not be afraid. What can man do to me?Isaiah 41:1010 Fear not, for I am with you; Be not dismayed, for I am your God. I will strengthen you, Yes, I will help you,Isaiah 43:22 When you pass through the waters, I will be with you; And through the rivers, they shall not overflow you. When you walk through the fire, you shall not be burned, Nor shall the flame scorch you.Isaiah 26:33 You will keep him in perfect peace, Whose mind is stayed on You, Because he trusts in You.John 14:2727 Peace I leave with you, My peace I give to you; not as the world gives do I give to you. Let not your heart be troubled, neither let it be afraid.1 Peter 5:77 casting all your care upon Him, for He cares for you.Jeremiah 31:33 …“Yes, I have loved you with an everlasting love;…Philippians 4:1919 And my God shall supply all your need according to His riches in glory by Christ Jesus.Hebrews 13:55 …For He Himself has said, “I will never leave you nor forsake you.”2 Corinthians 1:2020 For all the promises of God in Him are Yes, and in Him Amen, to the glory of God through us.

Invités :Benjamin Morel, constitutionnaliste maître de conférences à l'Université Panthéon-Assas et auteur du « Nouveau régime ou l'impossible parlementarisme » (Ed. Passés-Composés, 2025) Eric Coquerel, député LFI de Seine-Saint-Denis et président de la Commission des finances de l'Assemblée NationaleHébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

John Maytham is joined by Dr Suhayfa Bhamjee, Senior Lecturer in Criminal Law at the University of KwaZulu-Natal. She argues that this was not merely a procedural lapse, but an incident with far-reaching consequences for the integrity of the National Prosecuting Authority. In a system built on transparency and the testing of evidence through cross-examination, the abrupt exit of the country’s top prosecutor has fuelled concerns about respect for due process, the authority of commissions of inquiry, and public confidence in the rule of law. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Longtemps cantonnée à son rôle d'opérateur ferroviaire national, la compagnie italienne Trenitalia a changé de dimension. Forte d'un plan d'investissement massif et déjà bien implantée en France, elle affiche désormais une ambition claire : devenir un acteur central du rail européen à grande vitesse. Si Trenitalia attire aujourd'hui l'attention, c'est d'abord par l'ampleur de ses moyens. La compagnie ferroviaire italienne prévoit un plan d'investissement de 100 milliards d'euros d'ici à 2030, un montant qui doit même doubler à l'horizon 2040. Une enveloppe spectaculaire, destinée en priorité à la modernisation du réseau italien, mais qui poursuit aussi un objectif plus large : préparer l'expansion européenne du groupe. Les dirigeants de Trenitalia ne s'en cachent d'ailleurs pas. Ils répètent régulièrement qu'ils considèrent désormais l'Europe comme leur marché intérieur. Derrière cette déclaration se dessine un projet ambitieux : la construction d'un « métro européen à grande vitesse », avec des trains rouges vifs ornés du drapeau italien, appelés à circuler à travers tout le continent. Plusieurs liaisons emblématiques ont déjà été annoncées comme Rome–Munich ou Milan–Munich. Mais le projet le plus symbolique reste celui d'un Paris–Londres, en concurrence directe avec Eurostar, envisagé à l'horizon 2030. À lire aussiTrain à grande vitesse: l'Europe met 500 milliards sur la table pour relier toutes ses capitales d'ici 2040 La France, vitrine et terrain d'essai grandeur nature de la stratégie Trenitalia Cette ambition européenne n'est pas théorique. Des trains italiens circulent déjà en France entre Paris, Lyon et Marseille depuis maintenant quatre ans. C'est même dans l'Hexagone que la stratégie européenne de Trenitalia est la plus visible. Son arrivée a eu des effets immédiats sur le marché : baisse des prix pouvant atteindre 30 %, augmentation des fréquences et pour l'opérateur historique SNCF, une obligation de réajuster son modèle, ses services et son offre sur ces axes très fréquentés. Pour autant, cette implantation a un coût. Trenitalia perd de l'argent en France avec près de 150 millions d'euros de pertes cumulées depuis son arrivée. La raison est simple : faire rouler des trains dans l'Hexagone est particulièrement cher, notamment en raison des péages ferroviaires payés à l'opérateur d'infrastructure. La direction assume pleinement cette situation. La rentabilité n'est pas attendue avant plusieurs années. L'objectif est clair : s'installer durablement sur le marché, quitte à accepter des pertes à court terme. La logique est celle d'un investissement de long terme. À lire aussiLa compagnie italienne Trenitalia lance son offre sur la ligne Paris-Marseille pour concurrencer la SNCF Frecciarossa, entre coopération, compétition et pari européen L'image de cet investissement, c'est le Frecciarossa, le TGV italien reconnaissable à sa livrée rouge, dont le nom signifie « flèche rouge ». Ce train de nouvelle génération a été conçu pour circuler sur plusieurs réseaux européens, un avantage stratégique majeur. Car en Europe, chaque pays dispose de ses propres normes techniques et systèmes de signalisation. Pouvoir franchir les frontières sans changer de train ni d'équipage permet de réduire les coûts, de simplifier l'exploitation et d'accélérer l'expansion internationale. Sur le papier, la stratégie est solide. Mais à l'échelle européenne, Trenitalia ne peut pas avancer seule. Faire circuler ses trains dans d'autres pays revient à concurrencer directement les opérateurs nationaux en place. La réponse tient en un mot : la « coopétition ». Ce mot-valise, contraction de coopération et compétition, résume la philosophie du groupe : coopérer avec les autres opérateurs pour harmoniser les normes et partager certaines infrastructures, tout en restant concurrents sur les prix et les services. Cette approche s'inscrit pleinement dans le grand projet de la Commission européenne, qui ambitionne de relier toutes les capitales du continent d'ici à 2040 grâce à un vaste réseau ferroviaire à grande vitesse. Un projet que Trenitalia semble avoir anticipé et sur lequel la compagnie italienne paraît déjà avoir un train d'avance. À lire aussiQuel avenir pour le train à grande vitesse en Afrique?

The FTC may be quietly reviving its controversial Click-to-Cancel rule — and companies with subscription or auto-renewal programs should take notice. After the Eighth Circuit vacated the original rule on procedural grounds, consumer groups petitioned the FTC to reopen the rulemaking, and the Commission has now invited public comment, signaling that federal scrutiny of cancellation practices is far from over. For legal, compliance, and marketing teams, this development underscores the ongoing risk around negative-option offers and the need to evaluate enrollment disclosures and cancellation flows now, not later. Hosted by Simone Roach. Based on a blog post by Gonzalo E. Mon, Donnelly L. McDowell, and Aaron J. Burstein.

Over the span of his illustrious career, Mike began by starting the first storefront law office in Canada, and establishing the UBC law school legal advice clinic (1968-71).  He then went on to serve for four terms as a Vancouver Alderman (1972-980), until he became a tremendously successful and articulate Mayor of Vancouver for three terms (1980-1986).  In that position he played a prominent role in establishing Vancouver as one of the world's most livable cities through effective land use and planning. Mike then moved on to serve as the 30th Premier of British Columbia (1991-1996), where he extended the boundaries of quality of life in urban areas, with the 1995 Growth Strategy Act. In that position he played a prominent role in establishing Vancouver as one of the world's most livable cities through effective land use and planning. Mike then moved on to serve as the 30th Premier of British Columbia (1991-1996), where he extended the boundaries of quality of life in urban areas, with the 1995 Growth Strategy Act. Among his many noteworthy achievements at that time was his success in safeguarding more than 12 percent of the province's land base, establishing 500 new protected areas. After retiring from politics, Mike made headlines in 2002, when a devastating six-metre fall left him partially paralyzed. He has shown incredible physical, emotional and spiritual strength in his remarkable recovery, and published a book about his ordeal called Plan B – One Man's Journey from Tragedy to Triumph. Following his accident, Mike became actively involved in spinal cord research and education, working with the Rick Hansen Man in Motion Foundation on International Collaboration on Repair Discoveries (I-CORD) and chairing the Spinal Cord Injury Quality of Life Advisory Group. As a self-described "recovering politician," Mike was appointed Federal Commissioner on the British Columbia Treaty Commission in 2003. He has always been an avid supporter of aboriginal economic development, and his commitment to the treaty process is long-standing; as Premier in 1992, he signed the agreement establishing the Commission – the neutral body responsible for facilitating treaty negotiations among the governments of Canada, B.C. and First Nations in B.C.  In recognition of Mike's exceptional community contributions, Simon Fraser University presented Mike with the 2019 President's Distinguished Community Leadership Award.

On this episode, we are joined by Jessie Perchaluk, an occupational therapist and Certified Hand Therapist who has taken a special interest in learning more about and implementing remote therapeutic monitoring (RTM) into her practice. Jessie shares with us the various ways that we can utilize RTM as an adjunct to the care we currently provide and how we can stay connected to our patients.Jessie Perchaluk, OTD, MS, OTR/L, CHT, CLT is an occupational therapist at NovaCare Rehabilitation (a division of Select Medical), and a core adjunct faculty member at Thomas Jefferson University in their hybrid MSOT program, as well as adjunct instructor at the Medical University of South Carolina's hybrid OTD program. She is a board-certified hand therapist and lymphedema therapist specializing in upper extremity and oncological rehabilitation, balancing full-time clinical practice with graduate-level teaching in functional anatomy, clinical skills, and upper extremity rehabilitation.With over eight years of experience, Jessie is passionate about delivering personalized, evidence and data informed care in order to restore function and improve quality of life. She is equally dedicated to advancing the profession through education, mentorship, and research. Jessie leads student fieldwork and capstone initiatives across Pennsylvania and Delaware for Select Medical, to which she has been nationally and locally recognized for her work.Jessie also serves on AOTA's Commission on Education as the fieldwork educator representative, contributing to national education policy and best practice initiatives. She combines her clinical knowledge and passion for furthering evidence and data informed care by continuing to be actively involved in ongoing research projects. Jessie is further advancing her knowledge in healthcare at Brown University in their Masters of Healthcare Leadership.When she is not working, Jessie enjoys spending time with her husband and three daughters. The views and opinions expressed in the Hands in Motion podcast are those of the guests and do not necessarily reflect the official policy or position of ASHT. Appearance on the podcast does not imply endorsement of any products, services or viewpoints discussed.

durée : 00:19:51 - Journal de 18h - Deux ans après l'attaque du 7 octobre en Israël, il n'y aura pas d'enquête indépendante, mais une commission "sur mesure" pour le gouvernement. Ce dernier donne son feu vert à l'instance, dont il pourra lui-même désigner les membres les familles de victimes dénoncent "un écran de fumée".

durée : 00:19:51 - Journal de 18h - Deux ans après l'attaque du 7 octobre en Israël, il n'y aura pas d'enquête indépendante, mais une commission "sur mesure" pour le gouvernement. Ce dernier donne son feu vert à l'instance, dont il pourra lui-même désigner les membres. Les familles de victimes dénoncent "un écran de fumée".

"The thought of recurrence is also a psychosocial issue for our patients. They're being monitored very closely for five years, so there's always that thought in the back of their head, 'What if the cancer comes back? What are the next steps? What am I going to do next?' It's really important that we have conversations with patients and their families about where they're at, what we're looking for, and reassure them that we'll be with them during this journey and help them through whatever next steps happen," ONS member Clara Beaver, DNP, RN, AOCNS®, ACNS-BC, manager of clinical education and clinical nurse specialist at Karmanos Cancer Institute in Detroit, MI, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about prostate cancer survivorship considerations for nurses. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0  Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by December 19, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to survivorship nursing considerations for people with prostate cancer. Episode Notes  Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 390: Prostate Cancer Treatment Considerations for Nurses Episode 387: Prostate Cancer Screening, Early Detection, and Disparities Episode 201: Which Survivorship Care Model Is Right for Your Patient? Episode 194: Sex Is a Component of Patient-Centered Care ONS Voice articles: APRNs Collaborate With PCPs on Shared Survivorship Care Models Exercise Before ADT Treatment Reduces Rate of Side Effects Frank Conversations Enhance Sexual and Reproductive Health Support During Cancer Here Are the Current Nutrition and Physical Activity Recommendations for Cancer Survivors Nursing Considerations for Prostate Cancer Survivorship Care Regular Physical Activity and Healthy Diet Lower Risk of All-Cause and Cardiac Mortality in Prostate Cancer Survivors Sexual Considerations for Patients With Cancer Sleep Disturbance Is Part of a Behavioral Symptom Cluster in Prostate Cancer Survivors ONS course: Essentials in Survivorship Care for the Advanced Practice Provider Clinical Journal of Oncology Nursing articles: A Patient-Specific, Goal-Oriented Exercise Algorithm for Men Receiving Androgen Deprivation Therapy Incorporating Nurse Navigation to Improve Cancer Survivorship Care Plan Delivery Prostate Cancer: Survivorship Care Case Study, Care Plan, and Commentaries The Role of the Advanced Practice Provider in Bone Health Management for the Prostate Cancer Population Oncology Nursing Forum articles: A Qualitative Exploration of Prostate Cancer Survivors Experiencing Psychological Distress: Loss of Self, Function, Connection, and Control Identification of Symptom Profiles in Prostate Cancer Survivors Sleep Hygiene Education, ReadiWatch™ Actigraphy, and Telehealth Cognitive Behavioral Training for Insomnia for People With Prostate Cancer Understanding Men's Experiences With Prostate Cancer Stigma: A Qualitative Study Other ONS resources: Late Effects of Cancer Treatment Huddle Card Survivorship Care Plan Huddle Card Survivorship Learning Library American Cancer Society (ACS): Living as a Prostate Cancer Survivor ACS prostate cancer survivorship studies To discuss the information in this episode with other oncology nurses, visit the ONS Communities.  To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Some of the most common late side effects [are] urinary, bowel, and sexual dysfunction issues. For urinary effects, it can include urgency and frequency, some incontinence, or a weak or slow urine stream that frequently bothers the patient after treatment. Bowel effects can happen such as constipation, diarrhea, or inflammation of the rectum, which can lead to bleeding or mucus discharge. And then erectile dysfunction is another side effect that patients with prostate cancer often deal with and have to work with their physicians on, depending on what they want with that function. Fatigue, lymphedema, and skin changes can also occur after treatment." TS 1:40 "If we can catch [prostate cancer] and take care of it at an early stage, overall survival is about 90%. If the disease is localized, it's 99%. If we can take out the prostate, radiate the prostate, we can do something with that—localized, 99% survival rate. If there's regional metastasis, it's about 90%. And if there's distant metastasis, it's about 30% survival." TS 3:55 "Prostate cancer recurs in about 20%–30% of patients within the first five years of initial treatment. ... There's not a lot of research out there that shows what can reduce risk, but what has been shown to be effective is regular exercise, quitting smoking, and eating a healthy diet. ... It's really important for our patients to understand the importance of having follow-up visits so that we can catch a recurrence quickly instead of waiting years down the road. Prostate cancer is usually a slow-growing disease, so if we can pick it up quickly in those revisits, we can start another treatment for the patient." TS 6:00 "Sexuality is not something many people are comfortable discussing, but we really need to talk with patients and let them know that this is normal. It is normal that you may have some sexual dysfunction. It's normal that you may not feel the way you did before. Talk to us about it, let us know where you're at, let us know what your goals are, because there are a lot of things we can do. There are medications we can use for impedance. There are devices and implants available to help the patient to support them and give them whatever their goal is for their sexuality." TS 9:41 "Providing survivorship care plans are important for these patients—something that can be sent off to everyone else that's caring for that patient. You have your primary care physician, urologist, oncologist, the oncology nurse, maybe a navigator, and [others] who are looking into this patient. So, giving that patient a survivor care plan and putting it with their files to include a summary of the treatment received, because most of the time a patient is not going to remember exactly what they received. A suggested schedule for follow-up exams—so again, if a primary care provider is not used to dealing with a patient with prostate cancer, they have something to go off of. A schedule of other tests they may need in the future including screening for other types of cancer. Are they a smoker? Do they need lung screening? Do they need any other screenings related to types of cancers? And then a list of possible late or long-term side effects." TS 15:16 "I think a lot of people know about the long-term sexual effects, but what we don't really talk about is the effect that it has on the patient's self-image. How they define themselves, how they look, their body image, their self-image. It's really important that we continue to discuss it with patients and make them comfortable when discussing their sexuality and their goals for sexuality. They may be having these self-image issues after treatment that they're just not telling us about and that can affect their quality of life." TS 18:38

A few years ago, John Haffner was digging in his White River Junction backyard when his shovel hit a glass bottle buried underground. Then he found another, and another — all with words like “remedy,” “tonic” and “quick cure” embossed on them. John wants to know why there are so many of these old bottles around and, more importantly, what was in them? Local historian and independent reporter Kelby Greene is on the case, unraveling the snake oil sensation that swept the Green Mountain State. You can find the web version of this story here.Reporting for this story was supported by a grant from Vermont Humanities, in partnership with the Vermont 250 Commission and JAM, Junction Arts and Media. For more, check out the podcast series Roadside Vermont.This episode was reported by Kelby Greene and produced by Josh Crane. Editing and additional production from the rest of the BLS team: Sabine Poux and Burgess Brown. Our executive producer is Angela Evancie. Theme music by Ty Gibbons; other music by Blue Dot Sessions.Special thanks to Catherine Hurley, Shirley Duso and Creighton Hall.As always, our journalism is better when you're a part of it: Ask a question about Vermont Sign up for the BLS newsletter Say hi on Instagram and Reddit @bravestatevt Drop us an email: hello@bravelittlestate.org Make a gift to support people-powered journalism Tell your friends about the show! Brave Little State is a production of Vermont Public and a proud member of the NPR Network.

   President Trump has announced the United States has surrounded Venezuela with a complete blockade of sanctioned oil tankers in an effort to cut off all the money flowing into that country.  At the same time, he's announced he will address the nation Wednesday night from the White House in a speech that's expected to feature accomplishments and plans for 2026.  Let's hope he stays on script.    Marco Rubio makes a bold statement about what will keep him from running for president in 2028.      The Royals seem to be infuriating everyone except the people that make the decision on whether they can build a ballpark at 119th and Nall.  The City of Lenexa is trying to pull another crazy liberal scam on its good citizens after failing with a homeless shelter.  Wait until you hear this joke.    There's a ton of reporting on Travis Kelce's future and we'll explain why you shouldn't be listening to any of it just yet.  Darryn Peterson sits for the 8th time in 12 games as KU gets an easy win.   Kansas State is losing its only good wide receiver to the transfer portal and our Final Final is not great news for KC.